相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
R. Gopalakrishnan et al.
ONCOGENE (2016)
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Brian K. Albrecht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
B. Tolani et al.
ONCOGENE (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Sarah Picaud et al.
CANCER RESEARCH (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
D. Cirstea et al.
LEUKEMIA (2013)
MYC addiction: a potential therapeutic target in MM
W. Michael Kuehl et al.
BLOOD (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
The Era of Combination Therapy in Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Pathogenesis of Myeloma
Kenneth C. Anderson et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
Shaila Rahman et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The ups and downs of Myc biology
Laura Soucek et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
L. Santo et al.
ONCOGENE (2010)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
N. Raje et al.
LEUKEMIA (2009)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
分享论文
